Prognostic Factors in Small Cell Lung Cancer: An Analysis of 874 Consecutive Patients
1986; Springer Science+Business Media; Linguagem: Inglês
10.1007/978-1-4613-2295-5_8
ISSN2509-8497
Autores Tópico(s)Peptidase Inhibition and Analysis
ResumoThe introduction of combination chemotherapy for the treatment of small cell lung cancer (SCC) has resulted in substantial improvements in overall survival duration and in the chances of being alive and disease-free two to three years from diagnosis. Current trials in patients aged ≤70–75 provide average values for median survival duration and two years disease-free survival of about 14–16 months and 10–20%, respectively, for patients with limited stage disease. The corresponding figures for extensive stage disease are around 8–11 months and 1–2% [1]. The prognostic differences between patients at opposite ends of the disease spectrum are thus considerable. Although variation in prognosis is less within each of the two disease stages it is great enough to produce both false positive and false negative interpretations of results from therapeutic trials. Prognostic factors i.e. variables with a well established relationship to the prognosis serve as indicators of this uncontrollable variation.
Referência(s)